Aktis Oncology (AKTS) stock

Cancer radiopharmaceuticals , market cap $937M

Radiopharmaceuticals for solid tumor cancers

Market cap $937M

$15.20

+1.74%

As of Wednesday's close · Live for Pro members at the open

Why is AKTS down?

Down 34% in 3 months, 26% under its 50-day average.

Down more than its industry: the 281 other stocks in it fell a median 16% over the same 3 months.

−1Volatility moves 7.0% a day with no profit or positive free cash flow over four quarters on file

Tell me next time AKTS moves

Free account, no card. An optional alert when AKTS moves or its score changes.

Or see it live, free until Friday morning. No account.

Quality Score

Below Average

In its industry

#126of 291

Biotech

Checks firing

2of 14

Trending down

From 52-week high

-55.5%

Below the 200-day

AKTS's Quality Score was unchanged on Wed, Nov 4, at 1.

Follow AKTS's trial news. Pro members can get an alert when Aktis Oncology files news, and see its trials, share raises, and its CEO's filings.

Get an alert when AKTS files news on its trialsSee it live, free until Friday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2026“…trial of AKY-2519 in other B7-H3 expressing solid tumors, including lung cancers, in the second half of 2026”Trial start · SEC filing · Aug 13

Key facts on AKTS

Key facts on AKTS
Holding it back	Moves 7.0% a day with no profit behind it
Latest filing	10-Q, Aug 13 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

What's next

Sat Jan 9: One year since its IPOListed Jan 9, 2026 at $18.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

AKTS catalysts

Coming up

After its last 3 reports it closed +7.0% on average, higher 3 of 3 times.

1 more coming up, with sizes and sources, for Pro members.Get in free →

What's next for AKTS, and how long its cash lasts

Next step the company has named

2H 2026“On track to initiate Phase 1b trial of AKY-2519 in other B7-H3 expressing solid tumors, including lung cancers, in the second half of 2026”Trial start · SEC filing · Aug 13

What it means: when a trial begins, or reaches the stage the company named.

Lead program: AKY-2519
Another trial: BActinium-1Phase 1 · Recruiting · 138 people · main data estimated Dec 2027 · NCT07581184

2 more trials, 2 more milestones and 5 filings, for Pro members.

Cash runway Jun 30 balance sheet

$82.5M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into 2029” (8-K, Aug 13).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Chief Medical Officer Akos Czibere sold 12,500 shares on Sep 23, under a planned sale. 7 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Matthew Roden buys or sells

For Pro members: every trade, and Matthew Roden’s 5 filings and quotes.

Get an alert when AKTS files news on its trialsSee it live, free until Friday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 18 daysFDA decisionIn 18 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $385MDeramiocelFDA decision due (PDUFA)
In 18 daysFDA decisionIn 18 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $1.0BMolgramostimFDA decision due (PDUFA)
In 48 daysFDA decisionIn 48 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.9BLorundrostatFDA decision due (PDUFA)

12 more FDA dates and 99 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 153 dates, ranked →

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on AKTS and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

AKTS has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on AKTS, and all 14 on every stock.Get in free →

AKTS RSI today: 35.7, below its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1435.7
Above 30, below 50.
MACD (12, 26, 9)Above signal
Crossed above its signal line 10 sessions ago.
50-day average$19.93
The price is 23.7% below it.
200-day average$20.94
The price is 27.4% below it.
50/200 crossDeath cross
The 50-day crossed below the 200-day on Oct 27.
ADX 1436.1
25 or more, with +DI below -DI.
Support$14.84
Swing low from Oct 16, 2.4% below the price.
Resistance$20.69
Swing high from Mar 16, 36.1% above the price.
High since listing$34.19
From Jun 30, 124.9% above the price.
Low since listing$13.96
From Nov 2, 8.2% below the price.
Chart patternFalling channel
Lines over the Oct 1 and Oct 29 highs and under the Jul 31 and Oct 16 lows.
Bollinger Bands (20, 2)Inside
The bands run from $14.35 to $18.06.
Volume0.6x
Against its 20-day average, for the time of day.

The deep dive on AKTS

What it does and how it makes money1 findingFor Pro members1 finding on what AKTS does and how it makes money, for Pro members
Where it stands2 findings1 offering of shares or notes since Jan 2026, $318M in all.SEC filing · Jan 9, 2026
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades AKTS, for Pro members

5 more findings on AKTS, each with its source, for Pro membersGet in free →

How AKTS ranks in Biotech

AKTS is #126 of 291 by Quality Score.

How AKTS ranks in Biotech
1	KNSAKiniksa Pharmaceuticals International	7/14	23
2	AMGNAmgen	8/14	23
3	ARQTArcutis Biotherapeutics	9/14	22
	AGENAgenus		Open for its score
	AGIOAgios Pharmaceuticals		Open for its score
	ALECAlector		Open for its score
	ALLOAllogene Therapeutics		Open for its score
126	AKTSAktis Oncology	2/14	1

When does AKTS report earnings, and what happens after?

Expected to report Thu Nov 12, after the close (in 8 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What AKTS reported on Aug 13, 2026

The quarter

The figures are not read from the release yet.

“The increase of $1.8 million was attributable to continued advancement of the Company’s research collaboration with Eli Lilly and Company, with revenue recognized over time using the cost incurred input method.”

The filing on EDGAR

Where the sales came from

AKTS's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“The increase in net loss of $6.0 million was primarily driven by higher operating expenses offset by interest income, net of $4.8 million in the quarter.”

From its results filing (SEC filing · Aug 13)

1 more sentence, for Pro members.

The numbers

Market value: $937M; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on AKTS: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →

+8.2%+8.0%+4.8%

Mar 30May 11Aug 13

Reported	When	Gap	Reaction	5 sessions
Aug 13, 2026After close	After close	+0.8%	+4.8%	+0.9%
May 11, 2026After close	After close	+0.3%	+8.0%	+1.9%
Mar 30, 2026After close	After close	+4.0%	+8.2%	+1.1%

AKTS closed higher after 3 of its last 3 reports.

Everyone reporting earnings next week

AKTS share count over time

Shares: 68.5 times the count a year ago (to Jun 30).

Offerings, shelves, and splits of AKTS, from its filings
From its filings	Filed
Raised $317.7M in a sale of shares, about 34% of its market value	Jan 9, 2026
Registered shares for sale (S-1)	Dec 19, 2025

Insiders trading AKTS

AKTS insider trades

3 insiders sold $3M across 9 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellKen Herrmann$86KDirectorat $24.56 on Jul 20, filed Jul 21

SellKen HerrmannDirector$86Kat $24.56 on Jul 20, filed Jul 21

All 9 insider filings on AKTS from the last six months, for Pro members.Get in free →

All AKTS insider trades

AKTS's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Akos CzibereChief Medical Officer · 4 trades
Shulamit Ron-BiggerChief Operating Officer · 3 trades
Ken HerrmannDirector · 3 trades
Oleg NodelmanDirector · 2 trades
Lloyd Mitchell SegalDirector

See insider trades by person

Which ETFs hold AKTS?

In ETFs: AKTS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Aktis Oncology

Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.

79 employeesBoston, MAaktisoncology.com

Listed on Nasdaq on Jan 9, 2026, and is 16% below its $18 offer price now. Its IPO filing and first days

AKTS's score card

Aktis Oncology (AKTS): Quality Score 1, Below Average, #126 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn AKTS's score around: 5 things
2 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayJul 21Ken Herrmann sold AKTS$86K at $24.56, filed Jul 21

Alerts are optional.

See AKTS's 14 chart checks

See it live, free until Friday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 4, 2026: AKTS's Quality Score is 1 (Below Average), #126 of 291 in Biotech. Insiders sold $3M in the last 6 months (Form 4).

Is AKTS a good stock to buy? What its Quality Score says

AKTS scores 1 today, which Breakaway calls Below Average. It is #126 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 34% in 3 months, 26% under its 50-⁠day average. Shares: 68.5 times the count a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is AKTS's Quality Score?

AKTS scores 1 today, which Breakaway calls Below Average (0 to 5). That is #126 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AKTS's 1.

Are insiders buying AKTS?

3 insiders sold $3M across 9 filings in the last 6 months. No open-⁠market buys on record. The newest is Ken Herrmann, Director, who sold $86K on Jul 20. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.